KSK Diagnostics Closes Series A Financing Round

KSK Diagnostics GmbH, a Hamburg, Germany-based developer of molecular point-of-care tests, closed a Series A financing round of undisclosed amount.

Backers included Innovationsstarter Fonds Hamburg and High-Tech Gründerfonds.

The company intends to use the funds for the development of molecular point-of-care diagnostic tests and subsequent market launch.

Co-founded by Dr. Stefan Kulick, Dr. Peter Scheinert and Dr. Guido Krupp, KSK Diagnostics uses isothermal amplification technology to develop molecular point-of-care diagnostic tests for patient-oriented diagnostics, which enable the doctor to make a diagnosis after 30 minutes and coordinate the treatment. In addition to the diagnosis of pathogens, the company’s tests are suited to quickly clarify issues related to tumour diagnostics.




Join the discussion